Aprotinin (Trasylol) does not reduce bleeding in primary total hip arthroplasty

Area of Science:

• Orthopedic Surgery
• Anesthesiology
• Pharmacology

Background:

• Primary total hip arthroplasty is associated with significant blood loss.
• Aprotinin (Trasylol) is an antifibrinolytic agent that has been investigated for its potential to reduce surgical bleeding.

Purpose of the Study:

• To evaluate the efficacy of aprotinin in reducing blood loss during primary total hip arthroplasty.
• To compare total blood loss, postoperative hemoglobin levels, and transfusion requirements between patients receiving aprotinin and those receiving a placebo.

Main Methods:

• A randomized, double-blind, controlled study was conducted with 60 patients undergoing primary total hip arthroplasty.
• Patients received either a preoperative bolus of aprotinin (1.5 x 10(6) KIU) or normal saline.
• Blood loss from the femoral canal, total operative blood loss, and transfusion requirements were measured and recorded.

Main Results:

• No statistically significant difference was observed in total blood loss between the aprotinin and saline groups.
• Postoperative hemoglobin levels and transfusion requirements were also similar between the two groups.
• A trend towards reduced blood loss from the femoral canal was noted in the aprotinin group, but this did not reach statistical significance.

Conclusions:

• Aprotinin did not demonstrate significant efficacy in reducing overall blood loss during primary total hip arthroplasty.
• The findings do not support the routine use of aprotinin for primary total hip arthroplasty.
• Further research may be needed to explore potential benefits in specific patient populations or surgical variations.